Blood cancers at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
36 organizations at ASCO 2027 present work in blood cancers: 30 drug developers, 3 diagnostics, technology and service companies and 3 advocacy groups, societies, cancer centers, publishers and agencies. 36 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–20 of 36 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
AbbVie North Chicago, IL | |
Global drugmaker whose cancer medicines include venetoclax and ibrutinib for blood cancers and the ADC mirvetuximab soravtansine for ovarian cancer. | Booth Exhibiting at Booth 27033 |
Acrotech Biopharma East Windsor, NJ | |
Specialty drug company commercializing approved cancer medicines in the US, including treatments for T-cell lymphoma. | Booth Exhibiting at Booth 10092 |
Adaptive Biotechnologies Seattle, WA | |
Immune-sequencing company whose clonoSEQ test measures minimal residual disease in myeloma, leukemia and lymphoma. | Booth Exhibiting at Booth 17151 |
American Society of Hematology Washington, DC | |
Professional society of hematologists supporting research, education and advocacy on blood diseases, with meetings, journals and awards. | Booth Exhibiting at Booth 10024 |
Amgen Thousand Oaks, CA | |
Biotechnology drugmaker with cancer medicines for lung, blood and colorectal cancers, including targeted therapies and bispecific T-cell engagers. | Booth Exhibiting at Booth 22025 |
Ascentage Pharma Suzhou, China | |
Drug developer focused on blood cancers, with the TKI olverembatinib and the Bcl-2 inhibitor lisaftoclax among its programs. | Booth Exhibiting at Booth 37103 |
Astellas Tokyo, Japan | |
Japanese drugmaker with cancer medicines including enzalutamide for prostate cancer, enfortumab vedotin for bladder cancer and zolbetuximab for gastric cancer. | Booth Exhibiting at Booth 15117 |
BeOne Medicines Basel, Switzerland | |
Global oncology company, formerly BeiGene, marketing zanubrutinib for blood cancers and the PD-1 antibody tislelizumab. | Booth Exhibiting at Booth 24021, 24033 |
Blood Cancer United Washington, DC | |
Blood cancer charity, formerly The Leukemia & Lymphoma Society, funding research and offering free patient information, support and access advocacy. | Booth Exhibiting at Booth 10022 |
Bristol Myers Squibb Lawrence Township, NJ | |
Global drugmaker with immuno-oncology medicines such as nivolumab, plus myeloma, lymphoma and other blood cancer drugs and CAR-T cell therapies. | Booth Exhibiting at Booth 15093 |
Cogent Biosciences Waltham, MA | |
Biotech preparing to launch the KIT inhibitor bezuclastinib for systemic mastocytosis and gastrointestinal stromal tumors. | Booth Exhibiting at Booth 26149 |
Dr. Reddy's Laboratories Hyderabad, India | |
Indian drugmaker of generic medicines, biosimilars and specialty products, with oncology among its major therapy areas. | Booth Exhibiting at Booth 10102 |
Eli Lilly Indianapolis, IN | |
Global drugmaker whose cancer medicines include abemaciclib for breast cancer, selpercatinib for RET-driven cancers and pirtobrutinib for blood cancers. | Booth Exhibiting at Booth 19079 |
Genentech South San Francisco, CA | |
Roche company and biotechnology drugmaker with cancer medicines for breast, lung and blood cancers, including atezolizumab and bispecific antibodies. | Booth Exhibiting at Booth 19001 |
Genmab Copenhagen, Denmark | |
Antibody drug developer behind epcoritamab for lymphoma and tisotumab vedotin for cervical cancer, with ADCs and bispecifics in development. | Booth Exhibiting at Booth 27131 |
Genomic Testing Cooperative Lake Forest, CA | |
Lab offering comprehensive genomic profiling of tumor DNA and RNA from tissue, blood and spinal fluid for solid and blood cancers. | Booth Exhibiting at Booth 15142 |
Geron Foster City, CA | |
Commercial-stage biotech marketing imetelstat (Rytelo), a telomerase inhibitor for lower-risk myelodysplastic syndromes. | Booth Exhibiting at Booth 14149 |
Glenmark Pharmaceuticals Mumbai, India | |
Indian maker of branded and generic medicines sold in 80+ countries; its Ichnos Glenmark Innovation arm develops multispecific antibodies for myeloma. | Booth Exhibiting at Booth 34142, 34143 · Ichnos Glenmark Innovation (IGI) |
GSK London, UK | |
Global drugmaker with cancer medicines for gynecologic and blood cancers, including the PD-1 antibody dostarlimab and myeloma treatments. | Booth Exhibiting at Booth 19059 |
Incyte Wilmington, DE | |
Drugmaker with ruxolitinib for myelofibrosis and other blood disorders, plus treatments for lymphoma, cholangiocarcinoma and Merkel cell carcinoma. | Booth Exhibiting at Booth 28092 |
Instantly find 20 buyers in blood cancers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction